WO2013167986A3 - Compositions and methods for the treatment of epilepsy - Google Patents

Compositions and methods for the treatment of epilepsy Download PDF

Info

Publication number
WO2013167986A3
WO2013167986A3 PCT/IB2013/050740 IB2013050740W WO2013167986A3 WO 2013167986 A3 WO2013167986 A3 WO 2013167986A3 IB 2013050740 W IB2013050740 W IB 2013050740W WO 2013167986 A3 WO2013167986 A3 WO 2013167986A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
formula
seizures
syndrome
compositions
Prior art date
Application number
PCT/IB2013/050740
Other languages
French (fr)
Other versions
WO2013167986A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Priority to CA2873016A priority Critical patent/CA2873016A1/en
Priority to EP13787779.1A priority patent/EP2846795A2/en
Priority to JP2015510893A priority patent/JP2015526385A/en
Priority to AU2013257707A priority patent/AU2013257707A1/en
Priority to SG11201407309XA priority patent/SG11201407309XA/en
Publication of WO2013167986A2 publication Critical patent/WO2013167986A2/en
Priority to PCT/IB2013/060667 priority patent/WO2014087367A2/en
Priority to ZA2014/08058A priority patent/ZA201408058B/en
Publication of WO2013167986A3 publication Critical patent/WO2013167986A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II); and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder, partial seizures, adjunctive therapy for partial, myoclonic, tonic-clonic seizures and schizophrenia, neuropathic pain, seizures, Tourette syndrome, Alzheimer's disease, autism, bipolar disorder and anxiety disorder, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotoaia, intermittent explosive disorder, borderline personality disorder, myotonia congenita and post-traumatic stress disorder.
PCT/IB2013/050740 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy WO2013167986A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2873016A CA2873016A1 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy
EP13787779.1A EP2846795A2 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy
JP2015510893A JP2015526385A (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy
AU2013257707A AU2013257707A1 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy
SG11201407309XA SG11201407309XA (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy
PCT/IB2013/060667 WO2014087367A2 (en) 2012-12-09 2013-12-05 Compositions and methods for the treatment of neurological diseases and its associated complications
ZA2014/08058A ZA201408058B (en) 2012-05-08 2014-11-04 Compositions and methods for the treatment of epilepsy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1791CH2012 2012-05-08
IN1791/CHE/2012 2012-05-08

Publications (2)

Publication Number Publication Date
WO2013167986A2 WO2013167986A2 (en) 2013-11-14
WO2013167986A3 true WO2013167986A3 (en) 2015-06-18

Family

ID=54187089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/050740 WO2013167986A2 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy

Country Status (7)

Country Link
EP (1) EP2846795A2 (en)
JP (1) JP2015526385A (en)
AU (1) AU2013257707A1 (en)
CA (1) CA2873016A1 (en)
SG (1) SG11201407309XA (en)
WO (1) WO2013167986A2 (en)
ZA (1) ZA201408058B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519334A (en) * 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド Prodrugs of antiplatelet drugs
CN104583162A (en) * 2012-07-03 2015-04-29 塞利克斯比奥私人有限公司 Compositions and methods for the treatment of moderate to severe pain
JP6766036B2 (en) * 2014-06-02 2020-10-07 ケトゲン インコーポレイテッド Compounds for the treatment of seizures and other central nervous system disorders and conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034606A1 (en) * 1995-05-05 1996-11-07 Novo Nordisk A/S Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
EP1806339A1 (en) * 2005-12-21 2007-07-11 Ucb, S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
WO2010132693A2 (en) * 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034606A1 (en) * 1995-05-05 1996-11-07 Novo Nordisk A/S Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
EP1806339A1 (en) * 2005-12-21 2007-07-11 Ucb, S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
WO2010132693A2 (en) * 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AS ABOVE *

Also Published As

Publication number Publication date
ZA201408058B (en) 2016-03-30
AU2013257707A1 (en) 2014-11-27
JP2015526385A (en) 2015-09-10
SG11201407309XA (en) 2014-12-30
EP2846795A2 (en) 2015-03-18
CA2873016A1 (en) 2013-11-14
WO2013167986A2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
WO2014087367A3 (en) Compositions and methods for the treatment of neurological diseases and its associated complications
PH12014502183A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CO6751271A2 (en) Imidazol [5,1-f] [1,2,4] triazines for the treatment of neurological disorders
UA113051C2 (en) HETEROCYCLIC DERIVATIVES AND THEIR APPLICATIONS IN THE TREATMENT OF NEUROLOGICAL DISORDERS
JO2910B1 (en) Organic Compounds
MX2010009752A (en) Oxadiazoanthracene compounds for the treatment of diabetes.
PH12015500883A1 (en) Heteroaromatic compounds as dopamide d1 ligands
CL2008002114A1 (en) Compounds derived from 1- (2,3-dihydrobenzo [1,4] dioxin-2-ylmethyl) azacycles-3-substituted; pharmaceutical composition; and use of the compound for the treatment of a stress-propagated mental disorder, Parkinson's disease, schizophrenia, attention deficit disorder, obsessive compulsive disorder, psychosis, among others.
IN2012DN00785A (en)
EA201491116A1 (en) DERIVATIVES 6-DIFTORMETYL-5,6-DIGIDRO-2H- [1,4] OXAZIN-3-AMINE
EP2416795A4 (en) Inhibitors of cognitive decline
BR112013021180A2 (en) substituted 6,7-dialkoxy-3-isoquinolinol derivatives as phosphodiesterase 10 inhibitors (pde10a)
WO2013167986A3 (en) Compositions and methods for the treatment of epilepsy
IN2012DN03846A (en)
AR079103A1 (en) MESILATE SALT COMPOSITE OF (S) -2- (4- (3-FLUORO-BENCILOXI) -BENCILAMINO) -PROPIONAMIDE, POLYMORPHIC FORM (NF6), PHARMACEUTICAL COMPOSITION, USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT AND ITS PROCESSES PREPARATION
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
EA201690971A1 (en) PYRIDO [4,3-b] PYRAZIN-2-CARBOXAMIDES AS NEUROGENOUS MEANS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
MX2014014808A (en) Tricyclic compounds as kat ii inhibitors.
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
MA37999B1 (en) Macrolide derivatives, their preparation and their therapeutic use
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
PH12015500059A1 (en) Pieprazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
MX2011005971A (en) Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative.
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2873016

Country of ref document: CA

Ref document number: 2015510893

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013787779

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013257707

Country of ref document: AU

Date of ref document: 20130129

Kind code of ref document: A